natgillin/translations-raw huggingface dataset:
Peritoneal cavity
Peritonealna votlina
Peritoneal dialysis patients*
bolniki na peritonealni dializi
Peritoneal haemorrhage, Retroperitoneal haematoma, Vomiting
peritonealna krvavitev, retroperitonealni hematom, bruhanje
Peritonitis is a known complication in patients receiving peritoneal dialysis and in a clinical study with sevelamer hydrochloride, a greater number of peritonitis cases were reported in the sevelamer group than in the control group.
Peritonitis je znan zaplet pri bolnikih, ki prejemajo peritonealno dializo, in v kliničnih študijah s sevelamerijev kloridom so poročali o več primerih peritonitisa v skupini, ki je prejemala sevelamer, kot v kontrolni skupini.
Peritonitis is a known complication in patients receiving peritoneal dialysis and in a clinical study with sevelamer hydrochloride, a greater number of peritonitis cases were reported in the sevelamer group than in the control group.
Peritonitis je znan zaplet pri bolnikih, ki prejemajo peritonealno dializo, in v kliničnih študijah s sevelamerijevim kloridom so poročali o več primerih peritonitisa v skupini, ki je prejemala sevelamer, kot v kontrolni skupini.
Peritonitis, gastric and hepatic disorders and gastrointestinal surgery
Peritonitis, težave želodca in jeter ter gastrointestinalni kirurški poseg
Peritonitis, Gastrooesophagal reflux disease, Abdominal distension, Gingival pain
peritonitis, gastroezofagealni refluks, napihnjen trebuh, boleče dlesni
peritonitis, pancreatitis, swollen tongue, duodenitis, gastroenteritis, glossitis
peritonitis, pankreatitis, otekel jezik, duodenitis, gastroenteritis, glositis
peritonitisb, gastroenteritis, diverticulitis, pancreatitis, enterocolitis, gastric ulcer, large intestinal ulcer, oesophagitis, ileusd
perforacija v prebavilihb,c, perforacija debelega črevesab,c, perforacija črevesab,c, peritonitisb, gastroenteritis, divertikulitis, pankreatitis, enterokolitis, želodčna razjeda, razjeda debelega črevesa, ezofagitis, ileusd
Perjeta 420 mg concentrate for solution for infusion
Perjeta 420 mg koncentrat za raztopino za infundiranje
Perjeta and trastuzumab can be given in any order.
Zdravilo Perjeta in trastuzumab lahko damo v katerem koli vrstnem redu.
Perjeta and trastuzumab may be resumed if the LVEF has recovered to > 45% or 40-45% associated with < 10% points below pretreatment value.
Zdravili Perjeta in trastuzumab lahko znova uvedemo, če se vrednost LVEF dvigne na > 45 % ali 40 do 45 %, pri čemer je padec manjši od 10 odstotnih točk glede na vrednosti pred zdravljenjem.
Perjeta and trastuzumab should be withheld for at least 3 weeks for any of the following:
Zdravljenje z zdravilom Perjeta in trastuzumabom je treba prekiniti za vsaj 3 tedne, če nastopi kar koli od navedenega:
Perjeta and trastuzumab were given at standard doses in a 3-weekly regimen.
Zdravilo Perjeta in trastuzumab so dajali v standardnih odmerkih po 3-tedenskem režimu.
Perjeta can also be used to treat earlier stages of breast cancer at high risk of coming back (i.e. locally advanced, inflammatory or early stage breast cancer), before the patient undergoes surgery.
Zdravilo se lahko uporablja tudi za zdravljenje zgodnjega stadija raka dojk z visokim tveganjem za ponovitev (na primer napredovalega ali vnetnega raka dojk ali raka dojk v zgodnjem stadiju) pred kirurškim posegom.
Perjeta can be used to treat metastatic breast cancer (cancer that has spread to other parts of the body) that has not already been treated with chemotherapy medicines or medicines designed to attach to HER2, or breast cancer that has come back after treatment and cannot be removed by surgery.
Zdravilo se lahko uporablja za zdravljenje metastatskega raka dojk (raka, ki se je razširil na druge dele telesa) pri bolnikih, ki se še niso zdravili s kemoterapijo ali z zdravili, ki delujejo tako, da se vežejo na beljakovino HER2, ali za zdravljenje raka dojk, ki se je po zdravljenju ponovil in ga ni mogoče odstraniti s kirurškim posegom.
Perjeta contains the active substance pertuzumab and is used to treat adult patients with breast cancer when:
Zdravilo Perjeta vsebuje zdravilno učinkovino pertuzumab.
Perjeta displayed linear pharmacokinetics within the recommended dose range.
V priporočenem območju odmerjanja je zdravilo Perjeta pokazalo linearno farmakokinetiko.
Perjeta has also been shown to improve the outcome of patients with earlier stages of breast cancer, when used with trastuzumab and chemotherapy.
Poleg tega je zdravilo Perjeta v kombinaciji s trastuzumabom in kemoterapijo izboljšalo zdravstveno stanje bolnikov z zgodnjim stadijem raka dojk.
Perjeta has also been studied in two main studies involving a total of 642 patients with earlier stages of breast cancer who were to undergo surgery.
Zdravilo Perjeta so proučili tudi v dveh glavnih študijah, ki sta vključevali skupno 642 bolnikov z zgodnjim stadijem raka dojk, in pri katerih naj bi bil opravljen kirurški poseg.
Perjeta has been associated with infusion reactions (see section 4.8).
Uporabo zdravila Perjeta so spremljale infuzijske reakcije (glejte poglavje 4.8).
Perjeta has been studied in one main study involving 808 adults with previously untreated HER2- positive metastatic breast cancer.
Zdravilo Perjeta so raziskali v eni glavni študiji, v katero je bilo vključenih 808 odraslih s predhodno nezdravljenim metastatskim HER2-pozitivnim rakom dojk.
Perjeta has not been studied in patients with: a pre-treatment LVEF value of ≤ 50%; a prior history of congestive heart failure (CHF); LVEF declines to < 50% during prior trastuzumab adjuvant therapy; or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to > 360 mg/m2 of doxorubicin or its equivalent.
Zdravila Perjeta niso proučevali pri bolnikih: z vrednostjo LVEF pred zdravljenjem < 50 %; z anamnezo kongestivnega srčnega popuščanja; s padcem LVEF na < 50 % med predhodnim adjuvantnim zdravljenjem s trastuzumabom; s stanji, ki bi lahko okvarila delovanje levega prekata, kot so npr. neurejena hipertenzija, nedavni miokardni infarkt, resne motnje srčnega ritma, ki so zahtevale zdravljenje, predhodna kumulativna izpostavljenostjo antraciklinu do > 360 mg/m2 doksorubicina ali njegovega ekvivalenta.
Perjeta in combination with trastuzumab and docetaxel
Zdravilo Perjeta v kombinaciji s trastuzumabom in docetakselom
Perjeta is a cancer medicine that contains the active substance pertuzumab.
Perjeta je zdravilo, ki vsebuje zdravilno učinkovino pertuzumab.
Perjeta is a concentrate for solution for infusion.
Zdravilo Perjeta je koncentrat za raztopino za infundiranje.
Perjeta is administered as an intravenous infusion.
Zdravilo Perjeta dajemo v obliki intravenske infuzije.
Perjeta is administered intravenously by infusion.
Zdravilo Perjeta se daje v intravenski infuziji, ki pa ne sme biti hitra.
Perjeta is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients (see section 4.3).
Zdravilo Perjeta je kontraindicirano pri bolnikih z znano preobčutljivostjo na pertuzumab ali katero koli pomožno snov v tem zdravilu (glejte poglavje 4.3).
Perjeta is for single use only and is administered intravenously by infusion.
Zdravilo Perjeta je za enkratno uporabo in ga dajemo z intravensko infuzijo.
Perjeta is given by infusion into a vein.
Zdravilo se daje z infundiranjem v veno.
Perjeta is given with other cancer treatments (trastuzumab and docetaxel).
Zdravilo Perjeta se daje skupaj s še dvema drugima zdraviloma proti raku (trastuzumabom in docetakselom).
Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence (see section 5.1)
Zdravilo Perjeta je v kombinaciji s trastuzumabom in kemoterapijo indicirano za neoadjuvantno zdravljenje odraslih bolnikov s HER2-pozitivnim, lokalno napredovanim, vnetnim rakom dojk ali zgodnjim stadijem raka dojk z visokim tveganjem za ponovitev (glejte poglavje 5.1).
Perjeta is used to treat adults with breast cancer which is ‘HER2-positive’ (where a specific protein called ‘HER2’ is found on the surface of the cancer cells).
Zdravilo Pereta se uporablja za zdravljenje odraslih s HER2-pozitivnim rakom dojk (rakom dojk, pri katerem se na površju rakavih celic pojavlja posebna beljakovina, imenovana HER2).
Perjeta must be permanently discontinued in case of NCI-CTCAE Grade 4 hypersensitivity reactions (anaphylaxis), bronchospasm or acute respiratory distress syndrome (see section 4.2).
Zdravilo Perjeta je treba dokončno ukiniti v primeru preobčutljivostne reakcije stopnje 4 po merilih NCI-CTCAE (anafilaksije), bronhospazma ali sindroma akutne dihalne stiske (glejte poglavje 4.2).
Perjeta should be administered for 3 to 6 cycles in combination with neoadjuvant trastuzumab and chemotherapy, as part of a treatment regimen for early breast cancer.
Pri neoadjuvantnem zdravljenju, ki predstavlja del zdravljenja zgodnjega raka dojk, je treba zdravilo Perjeta dajati 3 do 6 ciklov v kombinaciji s trastuzumabom in kemoterapijo.
Perjeta was given intravenously at an initial dose of 840 mg, followed by 420 mg every three weeks.
Zdravilo Perjeta so dali intravensko v uvajalnem odmerku 840 mg, nato pa v odmerku 420 mg vsake tri tedne.
Perjeta+ Trastuzumab+ FEC Perjeta+ Trastuzumab
Perjeta + trastuzumab
Permanent AF with an AF duration >6 months (or duration unknown) and attempts to restore sinus rhythm no longer considered: If permanent AF develops, treatment with MULTAQ should be discontinued.
Permanentno AF, ki traja 6 mesecev ali dlje (ali njeno trajanje ni znano) in poskusi za obnovitev sinusnega ritma niso več predvideni: Če se pojavi permanentna (trajna) AF, je treba zdravljenje z zdravilom MULTAQ ukiniti.
Permanent AF with an AF duration ≥6 months (or duration unknown) and attempts to restore sinus rhythm no longer considered by the physician
Permanentna (trajna) AF ki traja 6 mesecev ali dlje (ali njeno trajanje ni znano) in zdravnik ne predvideva več poskusov za obnovitev sinusnega ritma.
Permanent discontinuation of Cotellic treatment should be considered if cardiac symptoms are attributed to Cotellic and do not improve after temporary interruption.
Če so srčni simptomi posledica zdravila Cotellic in se po prehodni prekinitvi njegove uporabe ne izboljšajo, je treba razmisliti o trajnem prenehanju zdravljenja z zdravilom Cotellic.
Permanent discontinuation of treatment was required in a greater proportion of patients receiving nivolumab in combination with ipilimumab than in those receiving nivolumab monotherapy for immune-related colitis (16% and 0.7%, respectively), immune-related hepatitis (9% and 0.9%), and immune-related endocrinopathies (2.5% and 0.1%).
Zdravljenje je bilo treba trajno prekiniti pri večjem deležu bolnikov, ki so se zdravili z nivolumabom v kombinaciji z ipilimumabom, kot pri bolnikih, ki so se zdravili z nivolumabom v monoterapiji: zaradi imunsko pogojenega kolitisa (16 % v primerjavi z 0,7 %), imunsko pogojenega hepatitisa (9 % v primerjavi z 0,9 %) ter imunsko pogojene endokrinopatije (2,5 % v primerjavi z 0,1 %).
Permanent discontinuation should be considered bases on clinical assessment of the onset, duration and severity of the observed toxicities.
O trajni ukinitvi zdravljenja je treba razmisliti glede na klinično oceno začetka, trajanja in resnosti opaženih toksičnosti.
Permanent treatment discontinuation was infrequently reported at 2%.
O dokončni prekinitvi zdravljenja so poročali redko, t.j. le pri 2% bolnikov.
Permanently discontinue
dokončna ukinitev
Permanently discontinue
trajno ukinite
Permanently discontinue
Zdravljenje je treba trajno prekiniti.
Permanently discontinue Avastin in patients with tracheoesophageal (TE) fistula or any Grade 4 fistula [US National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v.3)].
Pri bolnikih s traheoezofagealno fistulo ali katero koli fistulo stopnje 4 [US National Cancer Institute – Common Terminology Criteria for Adverse Events (NCI-CTCAE v.3)] zdravilo Avastin dokončno ukinemo.
Permanently discontinue DARZALEX if the patient experiences a ≥ Grade 3 infusion-related symptom at the subsequent infusion.
Če se pri naslednji infuziji pri bolniku ponovno pojavijo simptomi infuzijske reakcije stopnje 3, je treba zdravilo DARZALEX dokončno ukiniti.
Permanently discontinue dinutuximab and GM-CSF or IL-2.
Dokončno prekinite dinutuksimab in GM-CSF ali IL-2.
Permanently discontinue dinutuximab and GM-CSF or IL-2.
Dokončno prekinite z dinutuksimabom in GM-CSF ali IL-2.
Permanently discontinue dinutuximab and GM-CSF or IL-2.
Prekinite dinutuksimab in GM-CSF ali IL-2 za preostali del cikla.
Permanently discontinue for recurrence.
Pri ponovitvi zdravljenje trajno prekinite.
Permanently discontinue if patients experience Grade 3 skin induration/fibrosis.
Trajno prekinite zdravljenje, če se pri bolnikih pojavijo kožne zatrdline/fibroza stopnje 3.
Permanently discontinue if symptoms do not resolve to Grade ≤ 2 after holding for 2 consecutive cycles
Trajno prekinite zdravljenje, če se simptomi ne izboljšajo do stopnje ≤ 2 po prekinitvi, ki je trajala 2 zaporedna cikla (6 tednov).
Permanently discontinue pazopanib.
Trajno prekinite uporabo pazopaniba.
Permanently discontinue TAGRISSO
Trajno ukinite zdravljenje z zdravilom TAGRISSO.
Permanently discontinue trametinib and dabrafenib for life-threatening pulmonary embolism.
Če gre za življenjsko nevarno pljučno embolijo, je treba bolniku dokončno ukiniti zdravljenje s trametinibom in dabrafenibom.
Permanently discontinue trametinib for patients diagnosed with treatment-related ILD or pneumonitis.
Pri bolnikih, ki imajo diagnosticirano z zdravljenjem povezano IBP ali pnevmonitis, trajno končajte zdravljenje s trametinibom.
Permanently discontinue YERVOY in patients with the following adverse reactions.
Pri bolnikih z naslednjimi neželenimi učinki je treba zdravljenje z zdravilom YERVOY trajno ukiniti.
Permanently discontinue Zykadia if no contributing concomitant medicinal product is identified.
Če za nobeno od sočasno uporabljanih zdravil ni ugotovljeno, da prispeva k razvoju bradikardije, dokončno ukinite zdravljenje z zdravilom Zykadia.
Permethrin acts on the nervous system of arthropods, such as insects and ticks, leading to their death.
Permetrin deluje na živčni sistem artropodov, kot so insekti in klopi, kar vodi v njihovo smrt.
Permethrin also acts as a mild repellent.
Permetrin deluje tudi kot blag repelent.
Perphenazine
perfenazin
Perphenazine Risperidone Thioridazine
perfenazin risperidon tioridazin
perphenazine, risperidone, thioridazine, midazolam (given by injection), buspirone, clorazepate, diazepam, estazolam, flurazepam and zolpidem (used to treat nevous system disorders) buprenorphine (used to treat opioid addiction and pain)
perfenazin, risperidon, tioridazin, midazolam (v obliki injekcij), buspiron, klorazepat, diazepam, estazolam, flurazepam in zolpidem (uporabljamo jih za zdravljenje bolezni živčevja). buprenorfin (uporabljamo ga za zdravljenje zasvojenosti z opioidi in lajšanje bolečine).
Persistence of anti-HA antibodies 180 days and 360 days after the first vaccination as measured by single radial hemolysis (SRH) and microneutralization (MN) assay in children and adolescents aged 3 to 17 years was as follows:
Perzistenca protiteles proti HA 180 dni in 360 dni po prvem odmerku cepiva, izmerjena z enkratno radialno hemolizo (SRH) in testom mikronevtralizacije (MN) po cepljenju otrok in mladostnikov, starih med 3 in 17 let je bila naslednja:
Persistence of antibodies after primary vaccination in this population was assessed by Hemagglutination Inhibition (HI), SRH, and MN assays.
Obstojnost protiteles po primarnem cepljenju v tej populaciji je bila ocenjena s testi zaviranja hemaglutinacije (HI – hemagglutination inhibition), SRH in MN.
Persistence of antibody response (postdose 3) has been observed for 10 years in adolescents who were 9-15 years of age at time of vaccination; 9 years in women, 16-23 years of age at time of vaccination; 6 years in men, 16-26 years of age at time of vaccination, and 8 years in women, 24-45 years of age at time of vaccination.
Trajanje odziva protiteles (po 3. odmerku) so 10 let opazovali pri mladostnikih, ob cepljenju starih od 9 do 15 let, 9 let pri ženskah, ob cepljenju starih od 16 do 23 let, 6 let pri moških, ob cepljenju starih od 16 do 26 let, in 8 let pri ženskah, ob cepljenju starih od 24 do 45 let.
Persistence of immune response and booster response in adolescents
Obstojnost imunskega odziva in odziv po poživitvenem odmerku pri mladostnikih
Persistence of immune response and booster response in children 2 to 10 years of age
Obstojnost imunskega odziva in odziv po poživitvenem odmerku pri otrocih, starih od 2 do 10 let
Persistence of immune response in adolescents aged 11-17 years of age
Trajanje imunskega odziva pri mladostnikih, starih od 11 do 17 let
Persistence of immune response in children aged 2-10 years
Trajanje imunskega odziva pri otrocih, starih od 2 do 10 let
Persistence of immune response in children aged 6-10 years
Trajanje imunskega odziva pri otrocih, starih od 6 do 10 let
Persistence of resistance–associated substitutions
Trajnost substitucij, ki so povezane z odpornostjo
Persistence of ZOSTAVAX efficacy was studied 4 to 7 years postvaccination in the STPS, which included 7,320 subjects previously vaccinated with ZOSTAVAX and 6,950 subjects previously vaccinated with placebo in the SPS (mean age at enrollment was 73.3 years); and 7 to 10 years postvaccination in the Long-term Persistence Substudy (LTPS), which included 6,867 subjects previously vaccinated with ZOSTAVAX (mean age at enrollment into the LTPS was 74.5 years).
Trajanje učinkovitosti cepiva ZOSTAVAX je bilo preučevano v obdobju od 4 do 7 let po cepljenju v študiji STPS, ki je zajela 7.320 oseb, predhodno cepljenih s cepivom ZOSTAVAX, in 6.950 oseb, predhodno cepljenih s placebom, v študiji SPS (povprečna starost ob vključitvi je bila 73,3 leta) ter v obdobju od 7 do 10 let po cepljenju v študiji LTPS, ki je zajela 6.867 oseb, predhodno cepljenih s cepivom ZOSTAVAX (povprečna starost ob vključitvi v študijo LTPS je bila 74,5 let).
Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.
Perzistentni alergijski rinitis je opredeljen kot prisotnost simptomov 4 dni na teden ali več ali več kot 4 tedne.
Persistent crying lasting 3 hours or more within 48 hours of vaccination
če je v 48 urah po cepljenju vztrajno in neutolažljivo jokal 3 ure ali dlje,
persistent crying lasting 3 hours or more within 48 hours of vaccination
če je v 48 urah po cepljenju vztrajno in neutolažljivo jokal 3 ure ali dlje;
Persistent crying lasting 3 hours or more within 48 hours of vaccination
če je v 48 urah po cepljenju vztrajno jokal 3 ure ali dlje, epileptične napade/krče z zvišano telesno temperaturo ali brez v 3 dneh po cepljenju;
Persistent crying lasting  3 hours, occurring within 48 hours.
Stalen, neutolažljiv jok, ki traja ≥ 3 ure in se pojavi v 48 urah.
Persistent crying lasting  3 hours, occurring within 48 hours.
Vztrajno jokanje, ki je trajalo ≥ 3 ure in se je pojavilo v 48 urah.
persistent eye pain and inflammation (if prolonged) new pain, weakness or discomfort in your thigh, hip or groin.
vztrajna bolečina in vnetje oči (če traja dlje), na novo nastala bolečina, šibkost ali neugodje v stegnih, kolku ali dimljah.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
bolečina in vnetje v očeh, ki trajata dlje časa, nova bolečina, šibkost ali nelagodje v stegnu, kolku ali dimljah.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
bolečina in vnetje v očeh, ki trajata dlje časa; nova bolečina, šibkost ali nelagodje v stegnu, kolku ali dimljah.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
vztrajajoča bolečina in vnetje v očesu, nova bolečina, šibkost ali neugodje v stegnu, kolku ali dimljah.
persistent eye pain and inflammation new pain, weakness or discomfort in your thigh, hip or groin.
vztrajna bolečina in vnetje oči, na novo nastala bolečina, oslabelost ali neugodje v stegnih, kolku ali dimljah.
persistent for > 4 weeks, or
traja > 4 tedne ali
persistent for ≥ 4 weeks, or
o persistentne in trajajo ≥ 4 tedne, ali
Persistent grade 2 (longer than 7 days)
Perzistentna stopnja 2 (dlje kot 7 dni)
Persistent infection that lasts for at least 6 months has also been shown to be a relevant surrogate marker for cervical cancer.
Persistentne okužbe, ki trajajo vsaj 6 mesecev, so bile dokazano relevantni nadomestni označevalec raka materničnega vratu.
Persistent itch (pruritus)
Trdovratna srbečica (pruritius)
Persistent muscle weakness or muscle pain (myopathy/myositis), muscle cramp
trdovratna šibkost mišic ali bolečina v mišicah (miopatija/miozitis), mišični krči
persistent numbness, tingling or pain in feet and/or hands (this may indicate the beginning of peripheral neuropathy, an adverse effect on the nerves), muscular weakness
trdovratna omrtvelost, mravljinčenje ali bolečine v stopalih in/ali dlaneh (to lahko naznanja začetek periferne nevropatije, neželenega učinka na živcih), mišična šibkost
Persistent or extreme sleepiness
Trajna ali izredna zaspanost
persistent or recurrent ischemic cardiac pain marked ECG changes (in particular ST-segment abnormalities) raised cardiac enzymes or markers (e.g.
trdovratno ali ponavljajočo se ishemično srčno bolečino, izrazitimi spremembami v EKG (zlasti z nepravilnostmi spojnice ST), zvišanjem vrednosti srčnih encimov ali markerjev (npr.
Persistent or recurring diarrhoea while on treatment may be a risk factor for the development of anal fistula.
Trajna ali ponavljajoča driska med zdravljenjem je lahko dejavnik tveganja za nastanek analne fistule.
persistent pain and/or non-healing of sores in the mouth or jaw (osteonecrosis of the jaw),
trajna bolečina in/ali razjede v ustih ali čeljustnici, ki se ne zacelijo (osteonekroza čeljustnice),
Persistent Pulmonary Hypertension in the Newborn (PPHN)
Persistentna pljučna hipertenzija pri novorojenčkih (PPHN)
Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia.
Kronična pulmonarna hipertenzija novorojenčka (PPHN – »pulmonary hypertension of the newborn«) se pojavlja kot primarna razvojna okvara ali kot posledica drugih bolezni, kot so mekonijski aspiracijski sindrom (MAS), pljučnica, sepsa, sindrom dihalne stiske pri novorojenčkih, prirojena diafragmalna hernija (CDH – »congenital diaphragmatic hernia«) in pljučna hipoplazija.
Persistent severe myelosuppression, may result in superinfection or haemorrhage.
Trdovratna huda mielosupresija lahko vodi do sekundarnih okužb ali krvavitev.
Persistent worsening of Functional Class due to PH
vztrajno poslabševanje funkcijskega razreda zaradi PH
persistent, inconsolable crying lasting 3 hours or more, occurring within 48 hours of vaccination.
talen, neutolažljiv jok, ki traja 3 ure ali več in se pojavi v 48 urah po cepljenju;
Persistent, inconsolable crying lasting  3 hours, occurring within 48 hours of vaccination.
Trajajoč in neutolažljiv jok, ki traja  3 ure in se pojavi v 48 urah po cepljenju.
Persistent, inconsolable crying lasting  3 hours, occurring within 48 hours of vaccination;
Stalen, neutolažljiv jok, ki traja ≥ 3 ure in se pojavi v 48 urah po cepljenju.
Persistent, inconsolable crying lasting  3 hours, occurring within 48 hours of vaccination;
Stalen, neutolažljiv jok, ki traja  3 ure in nastopi v 48 urah po cepljenju.